WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 15-Jul-2015 (Data received as of 10-Jul-2015)
Next overall update Fall 2015
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 1'6101 Infant (under 12 months) mortality rate: 442
GDP / capita (US$): 5'8331 Child (under 5 years) mortality rate: 562

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 1'267'402  1'252'140  1'236'687  1'221'156  1'205'625  1'042'262  868'891  698'966 
Births 25'519  25'595  25'642  25'666  25'682  26'726  26'665  24'511 
Surviving infants 24'452  24'492  24'504  24'493  24'474  25'054  24'521  21'953 
Pop. less than 5 years 121'977  121'293  120'581  120'466  121'283  122'974  119'128  103'456 
Pop. less than 15 years 364'331  364'250  363'817  363'548  363'764  356'661  325'836  274'586 
Female 15-49 years 327'827  323'710  319'537  315'170  310'529  260'502  206'043  162'250 

Number of reported case

(Click for retrospective incidence data for India)
Diphtheria 6'094  3'133  2'525  4'233  3'434  5'125  8'425  39'231 
Japanese encephalitis 1'657  1'078  1'214  555 
Measles 24'977  13'822  18'668  33'634  31'458  38'835  89'612  114'036 
Mumps
Pertussis 46'706  31'089  44'154  39'091  40'508  31'431  112'416  320'109 
Polio* 43  265  10'408  18'975 
Rubella 4'870  3'698  1'232 
Rubella (CRS)
Tetanus (neonatal) 492  415  588  734  521  3'287  9'313 
Tetanus (total)** 5'017  2'814  2'404  2'843  1'756  8'997  23'356  45'948 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for India)
Vaccine year result method % card seen                                                
BCG 2008  87  CES   52  93  92  99*  99*  96  99*  99* 
DTP1 2008  83  CES   52  88  99  90  90  94 
DTP3 2008  72  CES   52  88  76  85  85  90  94  99*  53 
DTP4          75 
IPV1         
HepB_BD          42  33  30 
HepB3 2008  59  CES   52  86  67  70  47  91 
Hib3          88  87 
JapEnc          36  69  65  63  37 
MCV1          88  88  85  85  87  89  91 
MCV2          56  42  50  30 
PCV1         
PCV3         
Pol3 2008  70  CES   52  87  88  85  85  90  95  99*  42 
Rota1         
Rota_last         
Rubella1         
TT2plus 1999  60  MICS     59  61  90  90  79  80  78  22 
PAB         
VAD1          58  70  90  90  88 
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for India)
BCG 91  91  90  90  89  74  66 
DTP1 90  90  89  89  86  74  88  25 
DTP3 83  83  82  82  79  58  70 
HepB3 70  70  73  44  38 
HepB_BD 37  37  23 
Hib3 20  20 
MCV1 83  83  83  84  82  56  56 
MCV2 51  51  36  27 
PAB 87  87  87  87  87  85  81  20 
PCV3
Pol3 82  82  79  79  76  57  66 
Rota_last

Number of districts in the country 674  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 0
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
100
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTwP 6, 10, 14 weeks; 16-24 months; 5 years; Yes
DTwPHibHepB 6, 10, 14 weeks; No
HepB Birth; 6, 10, 14 weeks; Yes
JE_LiveAtd 9, 16-24 months; No
Measles 9, 16-24 months; Yes
OPV birth; 6, 10, 14 weeks; 16-24 months; Yes
TT 10, 16 years; Yes and pregnant women
VitaminA 9, 18, 24, 30, 36, 42 months; Yes

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2013-2017  2013-2017  2010-2017  2010-2017  2005-10  2005-10  2005-10 
Nº of districts with microplans that include activities to raise immunization coverage number 674    657    644     

System performance

Total Nº districts in country number 674  659  657  645  644  655  644 
Nº districts with DTP3 coverage >=80% number 561  530  414 
% of districts with DTP3 coverage >=80% From 0 to 100% 87  81  64 
Nº districts with measles (MCV1) coverage >=95% number       461    320  228 
% of districts with MCV1 coverage >=95% From 0 to 100%     71    49  35 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes     
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100% 80  77  100  100  100     

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes     

Sources

 1  "The 2015 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.